Allena Pharmaceuticals, Inc.
ALNAQ · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $20,383 | $20,383 | $37,244 | $26,376 |
| G&A Expenses | $11,603 | $11,603 | $9,676 | $8,641 |
| SG&A Expenses | $11,603 | $11,603 | $9,676 | $9,217 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $576 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $31,986 | $31,986 | $46,920 | $35,593 |
| Operating Income | -$32,335 | -$31,986 | -$46,920 | -$35,593 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$510 | -$859 | $0 | -$55 |
| Pre-Tax Income | -$32,845 | -$32,845 | -$47,339 | -$35,648 |
| Tax Expense | $510 | $0 | $0 | -$55 |
| Net Income | -$33,355 | -$32,845 | -$47,339 | -$35,648 |
| % Margin | – | – | – | – |
| EPS | -1.03 | -1.01 | -2.13 | -1.72 |
| % Growth | -2% | 52.6% | -23.8% | – |
| EPS Diluted | -1.03 | -1.01 | -2.13 | -1.72 |
| Weighted Avg Shares Out | 32,507 | 32,507 | 22,181 | 20,741 |
| Weighted Avg Shares Out Dil | 32,507 | 32,507 | 22,181 | 20,741 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $510 | -$510 | $270 | $575 |
| Depreciation & Amortization | $363 | $166 | $163 | $78 |
| EBITDA | -$31,972 | -$33,189 | -$47,176 | -$35,570 |
| % Margin | – | – | – | – |